Related Experiment Videos
Nontransplant treatment of tyrosinemia
1Department of Clinical Chemistry, Göteborg University, Sahlgrenska University Hospital, Gothenburg, Sweden. Elisabeth.Holme@clinchem.gu.se
Insights
Nitisinone (NTBC) therapy significantly improves survival for acute tyrosinemia patients, reducing liver transplant needs. Early NTBC treatment minimizes hepatocellular carcinoma (HCC) risk, but late treatment necessitates individualized malignancy risk assessment.
Area of Science:
- Biochemistry
- Hepatology
- Pediatric Medicine
Background:
- Acute tyrosinemia is a rare genetic disorder affecting amino acid metabolism.
- Hepatocellular carcinoma (HCC) is a severe complication of acute tyrosinemia.
- Liver transplantation was historically the primary treatment for severe cases.
Purpose of the Study:
- To evaluate the long-term efficacy and safety of NTBC treatment in acute tyrosinemia.
- To assess the risk of HCC in patients treated with NTBC, stratified by treatment initiation time.
- To determine the impact of NTBC on preventing porphyric crises.
Main Methods:
- Retrospective analysis of patients with acute tyrosinemia treated with NTBC.
- Stratification of patients based on early versus late initiation of NTBC therapy.
- Long-term follow-up to monitor for HCC development and other adverse events.
Main Results:
- NTBC treatment dramatically improved survival and reduced the need for early childhood liver transplantation.
- In patients starting NTBC early, only 1% developed HCC within the first year, with no further cases up to 9 years.
- Patients with late NTBC initiation face a considerable risk of liver malignancy, requiring individual risk evaluation.
- Medication adherence prevented porphyric crises, and NTBC was generally well-tolerated with minimal adverse effects.
Conclusions:
- Early NTBC treatment is highly effective in improving survival and preventing HCC in acute tyrosinemia.
- Individualized risk assessment for liver malignancy is crucial for patients with late NTBC treatment.
- NTBC is a safe and effective therapeutic option for managing acute tyrosinemia.
Abstract:
NTBC treatment has greatly improved the survival of patients with acute tyrosinemia and has reduced the need for liver transplantation during early childhood. In patients in whom treatment with NTBC was started early in life, 2 cases (1%) of HCC have occurred during the first year of treatment, but no further cases have occurred among these patients, who have been followed for up to 9 years. In patients with late start of NTBC treatment, there is a considerable risk for liver malignancy. The risk for malignancy in this group of patients must be evaluated on an individual basis, taking into account the phenotype and clinical status of the patient. Porphyric crises are not seen in patients who comply with the medication regimen. NTBC is a well-tolerated drug with few adverse effects.